Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Trial Profile

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Palbociclib (Primary) ; Capecitabine; Epirubicin; Exemestane; Fulvestrant; Letrozole; Paclitaxel; Tamoxifen; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PADMA
  • Most Recent Events

    • 18 Sep 2018 Planned number of patients changed from 360 to 260.
    • 18 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 30 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top